BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Drug Patent Profile

Which patents cover Betamethasone Acetate And Betamethasone Sodium Phosphate, and when can generic versions of Betamethasone Acetate And Betamethasone Sodium Phosphate launch?

Betamethasone Acetate And Betamethasone Sodium Phosphate is a drug marketed by Am Regent and Hikma and is included in two NDAs.

The generic ingredient in BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betamethasone Acetate And Betamethasone Sodium Phosphate

A generic version of BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE was approved as betamethasone acetate; betamethasone sodium phosphate by AM REGENT on July 31^st, 2009.

Summary for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
DailyMed Link:	BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE at DailyMed

Recent Clinical Trials for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shehab Ahmed Hamad	PHASE3
Tel-Aviv Sourasky Medical Center	N/A
University of Kentucky	Early Phase 1

See all BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE clinical trials

Pharmacology for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE	betamethasone acetate; betamethasone sodium phosphate	INJECTABLE;INJECTION	090747-001	Jul 31, 2009	AB	RX	No	No
Hikma	BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE	betamethasone acetate; betamethasone sodium phosphate	INJECTABLE;INJECTION	077838-001	Jan 17, 2023	AB	RX	No	No

Market Dynamics and Financial Trajectory for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Last updated: February 11, 2026

Market Overview

Betamethasone acetate and betamethasone sodium phosphate are corticosteroid formulations used predominantly in anti-inflammatory and immunosuppressive therapies. These drugs are primarily administered via injection for conditions such as allergic reactions, arthritis, skin conditions, and certain endocrine disorders.

Key Market Drivers

• Growing Prevalence of Autoimmune and Inflammatory Diseases: Increased incidence of rheumatoid arthritis, asthma, and allergic conditions strengthen demand for corticosteroids.
• Expansion of Injectable Formulations: Preference for injectable corticosteroids in clinical settings sustains growth.
• Regulatory Approvals: New approvals in emerging markets expand access and utilization.
• Cost-Effectiveness: These formulations are cheaper alternatives compared to biologics, supporting their continued use.

Market Challenges

• Side Effect Profile: Long-term use associated with side effects like osteoporosis, adrenal suppression, and infection risk.
• Generic Competition: Widespread generic manufacturing limits pricing power.
• Regulatory Scrutiny: Tightening drug safety regulations and reporting requirements increase compliance costs.

Market Size and Revenue Insights

• The global corticosteroids market was valued at approximately USD 725 million in 2021.
• Betamethasone formulations account for an estimated 15-20% of that market segment.
• Projected Compound Annual Growth Rate (CAGR) from 2022-2030: approximately 3.5%–4% (source: [1]).

Geographic Breakdown

Region	Market Share (2022)	Growth Rate (2022–2030)	Key Factors
North America	45%	3.2%	High prevalence of autoimmune diseases, advanced healthcare infrastructure
Europe	25%	3.6%	Strong regulatory environment, aging population
Asia-Pacific	20%	5.0%	Rapidly expanding healthcare markets, rising awareness
Rest of World	10%	2.8%	Limited access, price sensitivity

Market Players

Major manufacturers include Pfizer, GlaxoSmithKline, Novartis, and local generic producers in emerging territories. Their strategies revolve around expanding manufacturing capacity, pipeline diversification, and targeted marketing.

Financial Trajectory

• Revenue Projections: Estimated CAGR of 3.5–4% through 2030, reaching approximately USD 1 billion globally.
• Pricing Trends: Slight decline expected due to generic competition, balanced by increased volume.
• R&D Investment: Minimal for established formulations; significant for combination therapies or novel delivery mechanisms.

Regulatory and Patent Landscape

• Existing patents for Betamethasone formulations have expired or are nearing expiry in many markets, fostering generics.
• Regulatory bodies emphasize biosimilarity, safety, and efficacy, influencing manufacturing and approval timelines.

Strategic Considerations

• Focus on manufacturing cost reductions.
• Explore combination therapies to extend lifecycle.
• Expand into emerging markets to offset saturated mature markets.

Key Takeaways

• The corticosteroids market, specifically betamethasone formulations, maintains steady growth driven by medical demand.
• The landscape challenges include generic competition and safety concerns, influencing pricing and R&D focus.
• Geographic expansion, especially into Asia-Pacific, offers growth opportunities.
• Revenue is projected to increase modestly, with a CAGR of roughly 3.5%–4% until 2030.

FAQs

1. What factors influence the pricing of betamethasone formulations?
Primarily, generic competition reduces prices, while regulatory costs and patent statuses impact premiums.

2. How do safety concerns affect market demand?
Adverse effects limit long-term use, but acute treatments sustain demand; improved formulations may mitigate side effects.

3. Are biosimilars impacting the market?
Yes, biosimilar and generic versions reduce prices, especially post-patent expiration.

4. What is the potential in emerging markets?
Rapid healthcare infrastructure development and increasing disease prevalence create substantial growth opportunities.

5. How does new drug formulation impact the market?
Innovations like sustained-release injectables can extend product lifecycle and market share.

Sources
[1] MarketsandMarkets, "Corticosteroids Market," 2022.